会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明申请
    • Flat panel display TV stand
    • 平板显示电视架
    • US20060214072A1
    • 2006-09-28
    • US11376933
    • 2006-03-16
    • Kyung Lee
    • Kyung Lee
    • F16M11/00G09G3/28
    • F16M13/02F16M11/046
    • A flat panel display TV stand makes it possible to stably install a TV equipped with a flat panel display (e.g. LCD or PDP) regardless of the type of wall (e.g. concrete wall, gypsum board wall, or wooden wall), on which the TV is to be installed, as well as the size of the TV. The stand can fully support the weight of the TV and hides wires and cables drawn from the TV. This provides an aesthetic appearance. In addition, the stand can additionally accommodate peripheral devices (e.g. DVD player or VCR), which are typically used together with the TV. As such, the stand can be used for various purposes.
    • 平板显示电视架可以稳定地安装配有平板显示器(例如LCD或PDP)的电视机,而不管墙壁类型(例如混凝土墙壁,石膏板墙壁或木墙),电视机 要安装,以及电视的大小。 支架可以完全支持电视的重量,并隐藏从电视机中抽出的电线和电缆。 这提供了审美的外观。 此外,支架还可以容纳通常与电视一起使用的外围设备(例如DVD播放器或VCR)。 因此,支架可用于各种目的。
    • 33. 发明申请
    • Multilayer-coated stent for controlled drug release and manufacturing method thereof
    • 用于受控药物释放的多层涂层支架及其制造方法
    • US20060161242A1
    • 2006-07-20
    • US11210807
    • 2005-08-25
    • Kyung LeeSeung ParkCheol Lee
    • Kyung LeeSeung ParkCheol Lee
    • A61F2/82B05D1/02
    • A61L31/16A61L31/10A61L2300/61A61L2420/08C08L29/04C08L53/02
    • The present invention provides a multilayer-coated stent for controlled drug release, comprising: a first base layer formed on a stent support and made of poly(ethylene-co-vinylacetate) or polystyrene-ethylene-butylene rubber polymer; a second coating layer formed on the first base layer and made of a biocompatible or a bioabsorbable polymer and a drug component; and a third coating layer formed on the second coating layer and made of a biocompatible or a bioabsorbable polymer and a drug component different from the drug component of the second coating layer. The inventive stent can deliver a broad range of therapeutic substances for a long time and prevent the early rapid release of the drug components in blood. Also, unlike the existing drug-coated stents, the inventive stent includes two kinds of drugs complementary to each other, but can optimize the efficacy of the drugs by differentiating the control of drug release according to time.
    • 本发明提供一种用于受控药物释放的多层涂层支架,包括:形成在支架上并由聚(乙烯 - 共 - 乙酸乙烯酯)或聚苯乙烯 - 乙烯 - 丁烯橡胶聚合物制成的第一基层; 形成在第一基底层上并由生物相容或生物可吸收的聚合物和药物成分制成的第二涂层; 以及形成在第二涂层上并由生物相容性或生物可吸收聚合物和不同于第二涂层的药物成分的药物成分制成的第三涂层。 本发明的支架可以长时间传递广泛的治疗物质,并且防止血液中药物成分的早期快速释放。 此外,与现有的药物涂层支架不同,本发明的支架包括彼此互补的两种药物,但可以通过根据时间区分药物释放的控制来优化药物的功效。
    • 39. 发明申请
    • Methods of screening for inhibitors of antiplasmin cleaving enzyme
    • 筛选抗肿瘤酶切割酶抑制剂的方法
    • US20080118933A1
    • 2008-05-22
    • US11986058
    • 2007-11-20
    • Patrick McKeeKyung LeeKenneth JacksonVictoria Christiansen
    • Patrick McKeeKyung LeeKenneth JacksonVictoria Christiansen
    • G01N33/53C12N9/68
    • C12Q1/37A61K38/00C07K14/745C07K14/8121C12N9/6421C12P21/06G01N2500/00
    • Human α2-antiplasmin (α2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or α2APpro and an N-terminally-shortened 452-residue “activated”-form, or α2APact. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than α2APpro and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of α2APpro to yield α2APact. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish α2AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin. Patients who are susceptible to atherosclerotic plaque formation or are susceptible to developing thrombi that compromise organ function will benefit by therapies providing such inhibitors on a long term basis.
    • 人α2 - 对映体蛋白(α2 AP)是消化纤维蛋白的蛋白水解酶纤溶酶的主要抑制剂。 两种形式的α2 AP在人血浆中循环:464残基的蛋白质,我们称之为“亲”型或α2亚基 / SUB>和N-末端缩短的452残基“活化”形式或α2亚类作用。 后者通过活化因子XIII与α2 P肽相比快速交联5倍,并使纤维蛋白对纤溶酶消化具有抗性。 本文已经鉴定了一种新的人血浆蛋白酶,其切割了α2 -ATP pro pro的Pro12-Asn13键,以产生α2亚基 。 该酶在本文中被鉴定为抗血小板裂解酶(APCE)。 循环APCE的新型抑制剂可以降低形成纤维蛋白或血凝块中的α2 AP抑制能力,从而使纤维蛋白沉积物或血块更容易被纤溶酶去除。 易受动脉粥样硬化斑块形成或容易发生危及器官功能的血栓的患者将通过长期提供这种抑制剂的疗法而受益。